Novartis enters RNAi area with Quark option deal
This article was originally published in Scrip
Executive Summary
Novartis is to pay $10 million for the option to obtain the global licence to develop and commercialise Quark Pharmaceuticals' p53 temporary inhibitor small interfering RNA (siRNA) drug QPI-1002. The drug is currently in Phase II clinical trials for the prevention of acute kidney disease (AKI) in patients undergoing cardiac surgery and for delayed graft function (DGF) in kidney transplant patients.